All In Biotech

Drug Trial Radar · NCT06243692

Lacosamide Versus Topiramate in Migraine

Lacosamide Versus Topiramate in Migraine, a Ranodmized Trial

Last checked: Nov 20, 2026Latest source record: Mar 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

600

Planned (sponsor's estimate)

Start

Feb 1, 2024

Primary completion

Feb 2, 2025

Study completion Feb 25, 2025

Sponsor

Lead sponsor
Kafrelsheikh UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 10 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Investigators aim to compare the effect of lacosamide versus topiramate in migraine by assessing the absolute reduction in MMD in each group, the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency.

Conditions

  • Migraine Disorders

Interventions

  • Lacosamide 50 MGDrug

    The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of treatment was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.

  • Topiramate 50Mg TabDrug

    The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of treatment was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change in migraine days per 28 daysTime frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kafr Elsheikh University Hospital

    Kafr ash Shaykh, Egypt · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.